In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.
Teva touts safety profile of once monthly schizophrenia therapy –
Olanzapine is an atypical antipsychotic and was first approved by the US Food and Drug Administration in 2009 by Eli Lilly. Image credit: Jonathan Weiss
September 23, 2024